{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T10:32:48Z","timestamp":1755599568870,"version":"3.37.3"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21fk0410028","JP22fk0410050","JP23fk0410050"],"award-info":[{"award-number":["JP21fk0410028","JP22fk0410050","JP23fk0410050"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Integrase strand transfer inhibitors (INSTIs) are recommended as first-line ART for people living with HIV (PLWH) in most guidelines. The INSTI-resistance-associated mutation E157Q, a highly prevalent (2%\u20135%) polymorphism of the HIV-1 (human immunodeficiency virus type 1) integrase gene, has limited data on optimal first-line ART regimens. We assessed the virological outcomes of various first-line ART regimens in PLWH with E157Q in real-world settings.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A multicentre retrospective observational study was conducted on PLWH who underwent integrase genotypic drug-resistance testing before ART initiation between 2008 and 2019 and were found to have E157Q. Viral suppression (&amp;lt;50\u2005copies\/mL) rate at 24 and 48\u2005weeks, time to viral suppression and time to viral rebound (\u2265100\u2005copies\/mL) were compared among the first-line ART regimens.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>E157Q was detected in 167 (4.1%) of 4043 ART-na\u00efve PLWH. Among them, 144 had available clinical data after ART initiation with a median follow-up of 1888\u2005days. Forty-five started protease inhibitors\u200a+\u200a2 NRTIs (PI group), 33 started first-generation INSTI (raltegravir or elvitegravir\/cobicistat)\u200a+\u200a2 NRTIs (INSTI-1 group), 58 started once-daily second-generation INSTI (dolutegravir or bictegravir)\u200a+\u200a2 NRTIs (INSTI-2 group) and eight started other regimens. In the multivariate analysis, the INSTI-2 group showed similar or favourable outcomes compared with the PI group for viral suppression rates, time to viral suppression and time to viral rebound. Two cases in the INSTI-1 group experienced virological failure.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The general guideline recommendation of second-generation INSTI-based first-line ART for most PLWH is also applicable to PLWH harbouring E157Q.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkad319","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T18:57:20Z","timestamp":1697741840000},"page":"2859-2868","source":"Crossref","is-referenced-by-count":5,"title":["Virological outcomes of various first-line ART regimens in patients harbouring HIV-1 E157Q integrase polymorphism: a multicentre retrospective study"],"prefix":"10.1093","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9223-6138","authenticated-orcid":false,"given":"Shunsuke","family":"Uno","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Keio University School of Medicine , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Gatanaga","sequence":"additional","affiliation":[{"name":"AIDS Clinical Center, National Center for Global Health and Medicine , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsunefusa","family":"Hayashida","sequence":"additional","affiliation":[{"name":"AIDS Clinical Center, National Center for Global Health and Medicine , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayumi","family":"Imahashi","sequence":"additional","affiliation":[{"name":"Clinical Research Center, National Hospital Organization Nagoya Medical Center , Aichi , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rumi","family":"Minami","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Immunology and Infectious diseases, Clinical Research Center, National Hospital Organization Kyushu Medical Center , Fukuoka , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiko","family":"Koga","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sei","family":"Samukawa","sequence":"additional","affiliation":[{"name":"Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine , Kanagawa , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai","family":"Watanabe","sequence":"additional","affiliation":[{"name":"AIDS Medical Center, National Hospital Organization Osaka National Hospital , Osaka , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruhisa","family":"Fujii","sequence":"additional","affiliation":[{"name":"Division of Transfusion Medicine, Hiroshima University Hospital , Hiroshima , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Tateyama","sequence":"additional","affiliation":[{"name":"Department of Infectious, Respiratory and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus , Okinawa , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideta","family":"Nakamura","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Division of Infectious, Respiratory, and Digestive Medicine, University of the Ryukyus Graduate School of Medicine , Okinawa , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuzo","family":"Matsushita","sequence":"additional","affiliation":[{"name":"Clinical Retrovirology, Joint Research Center for Human Retrovirus Infection, Kumamoto University , Kumamoto , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Yoshino","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Teikyo University School of Medicine , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Endo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hokkaido University Hospital , Sapporo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahide","family":"Horiba","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, NHO Higashisaitama National Hospital , Saitama , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshibumi","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Chiba University Hospital , Chiba , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4588-5845","authenticated-orcid":false,"given":"Hiroshi","family":"Moro","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences , Niigata , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetoshi","family":"Igari","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Chiba University Hospital , Chiba , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Yoshida","sequence":"additional","affiliation":[{"name":"School of Medical Technology, Health Science University of Hokkaido , Hokkaido , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0941-271X","authenticated-orcid":false,"given":"Takanori","family":"Teshima","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hokkaido University Hospital , Sapporo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8967-4954","authenticated-orcid":false,"given":"Hideaki","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine , Kanagawa , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masako","family":"Nishizawa","sequence":"additional","affiliation":[{"name":"AIDS Research Center, National Institute of Infectious Diseases , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Yokomaku","sequence":"additional","affiliation":[{"name":"Clinical Research Center, National Hospital Organization Nagoya Medical Center , Aichi , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9269-4828","authenticated-orcid":false,"given":"Yasumasa","family":"Iwatani","sequence":"additional","affiliation":[{"name":"Clinical Research Center, National Hospital Organization Nagoya Medical Center , Aichi , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuko","family":"Hachiya","sequence":"additional","affiliation":[{"name":"Clinical Research Center, National Hospital Organization Nagoya Medical Center , Aichi , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Kato","sequence":"additional","affiliation":[{"name":"Hanah MediTech, Co. Ltd. , Tokyo , Japan"},{"name":"Department of Microbiology and Immunology, Keio University School of Medicine , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Keio University School of Medicine , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhisa","family":"Yoshimura","sequence":"additional","affiliation":[{"name":"Tokyo Metropolitan Institute of Public Health , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Sugiura","sequence":"additional","affiliation":[{"name":"Center for Clinical Sciences, National Center for Global Health and Medicine , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0384-0963","authenticated-orcid":false,"given":"Tadashi","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo , Tokyo , Japan"},{"name":"AIDS Research Center, National Institute of Infectious Diseases , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,10,19]]},"reference":[{"key":"2023120106051378500_dkad319-B1","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S0140-6736(09)60918-1","article-title":"Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial","volume":"374","author":"Rey","year":"2009","journal-title":"Lancet"},{"key":"2023120106051378500_dkad319-B2","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","article-title":"Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48\u2005week results from the randomised, double-blind, non-inferiority SPRING-2 study","volume":"381","author":"Raffi","year":"2013","journal-title":"Lancet"},{"author":"European AIDS Clinical Society","key":"2023120106051378500_dkad319-B3"},{"author":"Panel on Antiretroviral Guidelines for Adults and Adolescents","key":"2023120106051378500_dkad319-B4"},{"key":"2023120106051378500_dkad319-B5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society-USA panel","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"author":"Stanford University HIV Drug Resistance Database","key":"2023120106051378500_dkad319-B6"},{"author":"French ANRS-MIE (National Agency for AIDS Research\u2014Emergent Infectious Diseases) AC43 Resistance group","key":"2023120106051378500_dkad319-B7"},{"author":"Stanford University HIV Drug Resistance Database","key":"2023120106051378500_dkad319-B8"},{"key":"2023120106051378500_dkad319-B9","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1093\/jac\/dkx511","article-title":"Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen","volume":"73","author":"Charpentier","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2023120106051378500_dkad319-B10","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1093\/jac\/dkv202","article-title":"Primary resistance to integrase strand-transfer inhibitors in Europe","volume":"70","author":"Casadell\u00e0","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2023120106051378500_dkad319-B11","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/QAI.0000000000001649","article-title":"Prevalence of primary drug resistance against HIV-1 integrase inhibitors in Canada","volume":"78","author":"Ji","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023120106051378500_dkad319-B12","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1128\/AAC.00397-09","article-title":"Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors","volume":"53","author":"Low","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2023120106051378500_dkad319-B13","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jgar.2017.05.011","article-title":"Drug resistance in B and non-B subtypes amongst subjects recently diagnosed as primary\/recent or chronic HIV-infected over the period 2013\u20132016: impact on susceptibility to first-line strategies including integrase strand-transfer inhibitors","volume":"10","author":"Andreis","year":"2017","journal-title":"J Glob Antimicrob Resist"},{"key":"2023120106051378500_dkad319-B14","doi-asserted-by":"crossref","first-page":"312","DOI":"10.11150\/kansenshogakuzasshi.93.312","article-title":"Prevalence of HIV-1 integrase polymorphisms and drug resistance mutations in newly diagnosed individuals with HIV-1 in the Tokai area","volume":"93","author":"Shigemi","year":"2019","journal-title":"Kansenshogaku Zasshi"},{"key":"2023120106051378500_dkad319-B15","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/jac\/dkz067","article-title":"Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice","volume":"74","author":"Alvarez","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2023120106051378500_dkad319-B16","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/cid\/ciac972","article-title":"Transmitted drug resistance to integrase-based first-line human immunodeficiency virus antiretroviral regimens in Mediterranean Europe","volume":"76","author":"de Salazar","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2023120106051378500_dkad319-B17","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1097\/QAD.0000000000001616","volume":"31","author":"Saladini","year":"2017","journal-title":"AIDS"},{"key":"2023120106051378500_dkad319-B18","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1093\/jac\/dkw109","article-title":"Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity","volume":"71","author":"Anstett","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2023120106051378500_dkad319-B19","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1002\/jmv.25564","article-title":"Antiviral activity of HIV-1 integrase strand-transfer inhibitors against mutants with integrase resistance-associated mutations and their frequency in treatment-na\u00efve individuals","volume":"91","author":"Margot","year":"2019","journal-title":"J Med Virol"},{"key":"2023120106051378500_dkad319-B20","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1128\/AAC.01645-21","article-title":"Emergence of resistance in HIV-1 integrase with dolutegravir treatment in a pediatric population from the IMPAACT P1093 study","volume":"66","author":"Vavro","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2023120106051378500_dkad319-B21","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1056\/NEJMoa1904340","article-title":"Dolutegravir-based or low-dose efavirenz-based regimen for the treatment of HIV-1","volume":"381","author":"Kouanfack","year":"2019","journal-title":"N Engl J Med"},{"key":"2023120106051378500_dkad319-B22","doi-asserted-by":"crossref","first-page":"e677","DOI":"10.1016\/S2352-3018(20)30238-1","article-title":"Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon","volume":"7","author":"Calmy","year":"2020","journal-title":"Lancet HIV"},{"key":"2023120106051378500_dkad319-B23","doi-asserted-by":"crossref","first-page":"e2134","DOI":"10.1093\/cid\/ciaa1614","article-title":"Predictors of virological failure and time to viral suppression of first-line integrase inhibitor-based antiretroviral treatment","volume":"73","author":"Pyngottu","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023120106051378500_dkad319-B24","doi-asserted-by":"crossref","first-page":"e02533","DOI":"10.1128\/AAC.02533-18","article-title":"Resistance analysis of bictegravir-emtricitabine-tenofovir alafenamide in HIV-1 treatment-naive patients through 48 weeks","volume":"63","author":"Acosta","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2023120106051378500_dkad319-B25","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1093\/jac\/dkv012","article-title":"Non-virological response to a dolutegravir-containing regimen in a patient harbouring a E157Q-mutated virus in the integrase region","volume":"70","author":"Danion","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2023120106051378500_dkad319-B26","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1128\/AAC.01228-07","article-title":"Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro","volume":"52","author":"Malet","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2023120106051378500_dkad319-B27","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/jac\/dkp182","article-title":"Rapid selection and archiving of mutation E157Q in HIV-1 DNA during short-term low-level replication on a raltegravir-containing regimen","volume":"64","author":"Ghosn","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2023120106051378500_dkad319-B28","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.ijid.2021.05.066","article-title":"Phylodynamic analysis reveals changing transmission dynamics of HIV-1 CRF01_AE in Japan from heterosexuals to men who have sex with men","volume":"108","author":"Otani","year":"2021","journal-title":"Int J Infect Dis"},{"key":"2023120106051378500_dkad319-B29","doi-asserted-by":"crossref","first-page":"e26086","DOI":"10.1002\/jia2.26086","article-title":"Association of demographics, HCV co-infection, HIV-1 subtypes and genetic clustering with late HIV diagnosis: a retrospective analysis from the Japanese Drug Resistance HIV-1 Surveillance Network","volume":"26","author":"Otani","year":"2023","journal-title":"J Int AIDS Soc"},{"key":"2023120106051378500_dkad319-B30","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/QAI.0000000000000861","article-title":"Characteristics of transmitted drug-resistant HIV-1 in recently infected treatment-naive patients in Japan","volume":"71","author":"Hattori","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023120106051378500_dkad319-B31","doi-asserted-by":"crossref","first-page":"e4724","DOI":"10.1371\/journal.pone.0004724","article-title":"Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update","volume":"4","author":"Bennett","year":"2009","journal-title":"PLoS ONE"},{"key":"2023120106051378500_dkad319-B32","doi-asserted-by":"crossref","first-page":"W647","DOI":"10.1093\/nar\/gkp371","article-title":"jpHMM: improving the reliability of recombination prediction in HIV-1","volume":"37","author":"Schultz","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"2023120106051378500_dkad319-B33","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1097\/QAD.0000000000002243","article-title":"E157q integrase strand-transfer inhibitor substitution in patients with acute\/recent HIV infection","volume":"33","author":"Ambrosioni","year":"2019","journal-title":"AIDS"},{"key":"2023120106051378500_dkad319-B34","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3018(15)00027-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study","volume":"2","author":"Molina","year":"2015","journal-title":"Lancet HIV"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/12\/2859\/53850419\/dkad319.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/12\/2859\/53850419\/dkad319.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T06:05:45Z","timestamp":1701410745000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/78\/12\/2859\/7323564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,19]]},"references-count":34,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,10,19]]},"published-print":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkad319","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published-other":{"date-parts":[[2023,12]]},"published":{"date-parts":[[2023,10,19]]}}}